Literature DB >> 14527512

4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes.

Hyeon-Woo Lee1, Kyung-Ok Nam, Su K Seo, Young H Kim, Hyun Kang, Byoung S Kwon.   

Abstract

4-1BB, a T cell co-stimulatory receptor, prolongs the survival and multiplication of CD4 T cells. Cross-linking 4-1BB stimulated expression of the anti-apoptotic genes bcl-XL and bcl-2, as well as of cyclins D2 and E, and inhibited expression of the cyclin-dependent kinase (cdk) inhibitor p27kip1. Ova-activated CD4 T cells of 4-1BB-deficient/DO11.10 TCR transgenic mice survived less well and underwent less expansion than cells of wild type DO11.10 TCR transgenic mice. These findings demonstrate that 4-1BB is a co-stimulatory molecule for CD4 T cell survival and expansion in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527512     DOI: 10.1016/s0008-8749(03)00169-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

1.  Study of relieving graft-versus-host disease by blocking CD137-CD137 ligand costimulatory pathway in vitro.

Authors:  Kailin Xu; Chaohong Li; Xiuying Pan; Bing Du
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

2.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.

Authors:  Sujita Sukumaran; Norihiro Watanabe; Pradip Bajgain; Kanchana Raja; Somala Mohammed; William E Fisher; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Cancer Discov       Date:  2018-06-07       Impact factor: 39.397

3.  Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

Authors:  Young H Kim; Beom K Choi; Kwang H Kim; Sang W Kang; Byoung S Kwon
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

Review 4.  Dying to protect: cell death and the control of T-cell homeostasis.

Authors:  Kun-Po Li; Sharmila Shanmuganad; Kaitlin Carroll; Jonathan D Katz; Michael B Jordan; David A Hildeman
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 5.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

6.  4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.

Authors:  Beom K Choi; Do Y Lee; Don G Lee; Young H Kim; Seon-Hee Kim; Ho S Oh; Chungyong Han; Byoung S Kwon
Journal:  Cell Mol Immunol       Date:  2016-03-14       Impact factor: 11.530

Review 7.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

Review 8.  The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.

Authors:  Panagiota Economopoulou; Ioannis Kotsantis; Amanda Psyrri
Journal:  ESMO Open       Date:  2017-02-13

9.  Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.

Authors:  Qiao Li; Takekazu Iuchi; Maria N Jure-Kunkel; Alfred E Chang
Journal:  Int J Biol Sci       Date:  2007-11-20       Impact factor: 6.580

10.  Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses.

Authors:  Seon-Hee Kim; Rohit Singh; Chungyong Han; Eunjung Cho; Yu I Kim; Don G Lee; Young H Kim; Sang Soo Kim; Dong Hoon Shin; Hye Jin You; Hyeon-Woo Lee; Byoung S Kwon; Beom K Choi
Journal:  Cell Mol Immunol       Date:  2020-08-31       Impact factor: 11.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.